Autoimmune Diseases  >>  Nerventra (laquinimod)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nerventra (laquinimod) / Active Biotech
NCT00349193 / 2004-003943-28: A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Completed
2
306
Europe, RoW
laquinimod 0.3, laquinimod 0.6, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
06/06
08/06
NCT01404117: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Withdrawn
2
0
US
Laquinimod 0.6, Laquinimod 1.2, Glatiramer Acetate or interferon-beta+ Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Multiple Sclerosis
12/13
01/14
NCT00745615 / 2005-004334-41: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Terminated
2
257
Europe, RoW
Laquinimod, TV-5600, Placebo
Teva Pharmaceutical Industries, Ltd.
Relapsing Remitting Multiple Sclerosis
07/17
07/17

Download Options